Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 10/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.70 |
| ▸ | CYP2B6 | P20813 | 5/20 | 0.70 |
| ▸ | CYP2E1 | P05181 | 4/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.63 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015514 | 0.85 | CYP2A6 (0.70) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL5017551 | 0.85 | CYP2A6 (0.70) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL8204568 | 0.85 | CYP2A6 (0.80) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL1132959 | 0.85 | CYP2A6 (0.70) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL5016762 | 0.85 | CYP2A6 (0.70) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL5493639 | 0.85 | CYP2A6 (0.70) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL5014459 | 0.84 | CYP2A6 (0.68) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL3604362 | 0.83 | CYP2A6 (1.00) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL7588204 | 0.82 | CYP2A6 (0.67) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL12478490 | 0.82 | CYP2A6 (0.76) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313751-B1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| US-6740642-B2 | ACTIVE AGAINST GRAM POSITIVE PATHOGENS SUCH AS STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PNEUMONIAE, GRAM NEGATIVE STRAINS SUCH AS HAEMOPHILUS INFLUENZAE; IMPROVED STABILITY | BASILEA PARMACEUTICA AG (CH) | 2004-05-25 | — | — | US | disclosed |
| US-20030199459-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2003-10-23 | — | — | US | disclosed |
| EP-1313751-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016380-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199459-A1 | Macrolides with antibacterial activity | MRPL21, MRPS22, MRPL12 | CYP2A6 405/4885CYP2C19 499/4885CYP3A4 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.